# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money d...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price ta...
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in...
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...
Upwardly Revised 2024-2025 Financial Guidance: FY 2024 and 2025 total revenue is now expected to be more than $400 millio...